TNF Inhibitor Prescribing For RA Nearly Doubles, Caremark Exec Says
Executive Summary
Treatment regimens for the tumor necrosis factor-alpha inhibitors Abbott's Humira (adalimumab) and Johnson & Johnson's Remicade (infliximab) may be becoming increasingly aggressive